Glucagon-Like Peptide-1 Receptor Agonists: all 1,407 studies that test it

Page 12 of 15. Open to participants first (306), then studies with results posted, then the rest; newest registration first within each.

• A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.CompletedNCT02920385Phase 1
• Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatWithdrawnNCT02920190Phase 4
• Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee OsteoarthritisCompletedNCT02910570Phase 4
• Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of ObesityCompletedNCT02909933Phase 4
• Incretin-based Therapy in Early Diagnosed Type 1 DiabetesCompletedNCT02908087Phase 2
• Liraglutide 3 mg for Knee OsteoarthritisCompletedNCT02905864Phase 4
• Incretin-based Therapy in Late Preclinical Type 1 DiabetesCompletedNCT02898506Phase 2
• Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DMStatus unknownNCT02887625Not applicable
• HbA1c Variability in Type II DiabetesActive, not recruitingNCT02879409Not applicable
• Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.CompletedNCT02877355Phase 1
• Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02870231Phase 1
• Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyCompletedNCT02860923Phase 3
• Long-acting Exenatide and Cognitive Decline in Dysglycemic PatientsStatus unknownNCT02847403Phase 3
• A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal FemalesCompletedNCT02845219Phase 1
• The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke VolunteersCompletedNCT02838589Phase 2
• Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 DiabetesCompletedNCT02832999Phase 4
• The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in StrokeStatus unknownNCT02829502Phase 2
• Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 DiabetesWithdrawnNCT02811484Phase 4
• Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMICompletedNCT02794402Phase 2
• Effect of Liraglutide on Clock GenesStatus unknownNCT02783196Not applicable
• A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT02773381Phase 1
• Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)CompletedNCT02770885Phase 2
• Liraglutide for HIV-associated Neurocognitive DisorderTerminatedNCT02743598Phase 4
• Exenatide and Impaired Hypoglycaemic Awareness in Type 1 DiabetesCompletedNCT02735031Phase 2/3
• Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismTerminatedNCT02721888Phase 4
• Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in HumansStatus unknownNCT02718950Phase 3
• A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.CompletedNCT02717858Phase 1
• A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsCompletedNCT02696148Phase 1
• Gut Hormones in Obesity, Nicotine and Alcohol DependenceStatus unknownNCT02690987Early Phase 1
• Effect of Exenatide on 24h-UAER in Patients With Diabetic NephropathyCompletedNCT02690883Phase 4
• Effect of GLP-1 on AngiogenesisCompletedNCT02686177Phase 4
• Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic HypoglycemiaCompletedNCT02685852Phase 1
• Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesTerminatedNCT02674893Phase 4
• GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryActive, not recruitingNCT02673931Not applicable
• Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian DescentCompletedNCT02660047Phase 4
• Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes PatientsCompletedNCT02655770Phase 4
• Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedNCT02650479Phase 1
• Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and BloodCompletedNCT02650206Phase 1
• Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes SubjectsCompletedNCT02621489Phase 4
• Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 DiabetesCompletedNCT02617654Phase 2
• Preoperative Condition in Giant Obese PatientsCompletedNCT02616003Phase 4
• Incretin-based Therapy in Preclinical Type 1 Diabetes in AdultsStatus unknownNCT02611232Phase 2
• Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary StenosisCompletedNCT02602600Phase 4
• Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
• The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying RateStatus unknownNCT02584582Phase 2/3
• Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial FunctionStatus unknownNCT02584075Phase 4
• Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once WeeklyCompletedNCT02557620Phase 1
• Antiproteinuric Effects of Liraglutide TreatmentCompletedNCT02545738Phase 4
• Treatment of Hypoglycemia Following Gastric Bypass SurgeryCompletedNCT02527993Phase 4
• Effects of Glucagon Like Peptide-1 on No-reflowStatus unknownNCT02507128Not applicable
• The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)Status unknownNCT02501850Phase 4
• Effects of Glucagon Like Peptide-1 on Haemodynamic ParametersStatus unknownNCT02490176Not applicable
• Improving Beta Cell Function in Mexican American Women With PrediabetesCompletedNCT02488057Phase 4
• Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary SyndromeCompletedNCT02483299Phase 4
• The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell FunctionCompletedNCT02473809Phase 4
• Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy StudyWithdrawnNCT02472717Phase 2
• Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMCompletedNCT02467920Phase 4
• Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesCompletedNCT02449603Phase 4
• Research of Intensive Lifestyle Intervention for PCOS Patients With IGTCompletedNCT02446834Not applicable
• GLP-1 Analogs for Neuroprotection After Cardiac ArrestCompletedNCT02442791Not applicable
• Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery PatientsCompletedNCT02432976Phase 2/3
• Cognitive Dysfunction and Glucagon-like Peptide-1 AgonistsCompletedNCT02423824Phase 3
• Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes SubjectsCompletedNCT02408705Phase 2
• COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI TrialCompletedNCT02404376Phase 3
• The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in HumansCompletedNCT02403284Phase 4
• Exenatide Once Weekly, Cardiovascular Risk and Type-2 DiabetesCompletedNCT02380521Phase 4
• The Lira Pump TrialCompletedNCT02351232Phase 2/3
• Autoinjector Device Assessment StudyCompletedNCT02349802Phase 1
• Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure PatientsStatus unknownNCT02344641Not applicable
• Effects of Liraglutide on ER Stress in Obese Patients With Type 2 DiabetesStatus unknownNCT02344186Phase 4
• A Comparison of Exenatide and Insulin GlargineCompletedNCT02325960Phase 4
• Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsCompletedNCT02320045Phase 1
• Liraglutide to Improve corONary Haemodynamics During Exercise streSSCompletedNCT02315001Phase 2
• Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body WeightCompletedNCT02313220Phase 2
• Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesCompletedNCT02303730Phase 4
• Trial for People With Established Type 2 Diabetes During RamadanCompletedNCT02292290Phase 4
• The Effect of Liraglutide in Patients With Prediabetes and Kidney FailureWithdrawnNCT02284230Phase 2
• Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy SubjectsCompletedNCT02249910Phase 1
• Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy SubjectsCompletedNCT02243098Phase 1
• Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02235961Phase 1
• Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of SemaglutideCompletedNCT02231684Phase 1
• Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid SecretionTerminatedNCT02231658Phase 1
• Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes MellitusWithdrawnNCT02229240Phase 3
• A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 DiabetesCompletedNCT02212067Phase 1
• Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02210871Phase 1
• Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsCompletedNCT02207348Phase 1
• Liraglutide Actions on the Liver: Effects on Glucose PhosphorylationWithdrawnNCT02198209Phase 4
• Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)CompletedNCT02194595Phase 3
• PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary SyndromeCompletedNCT02187250Phase 4
• Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsCompletedNCT02172313Phase 1
• GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity MenCompletedNCT02170324Phase 4
• Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes MellitusStatus unknownNCT02162550Phase 4
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02161588Phase 1
• A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 DiabetesCompletedNCT02147431Phase 1
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02146079Phase 1
• Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With PrediabetesCompletedNCT02140983Phase 1
• Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential TherapyStatus unknownNCT02129985Phase 4
• Cardioprotective Effects of GLP-1 and Their MechanismsCompletedNCT02128022Phase 1
• Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory StatusStatus unknownNCT02118376Not applicable
• Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin InjectionsCompletedNCT02113332Phase 2

← Glucagon-Like Peptide-1 Receptor Agonists overview